Trials / Unknown
UnknownNCT03598179
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
A Single-center, Open Study Evaluating Efficacy and Safety of XLCART001（CD-19） Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The trial is a single arm, single-center, non-randomized clinical trial which is designed to evaluate the efficacy and safety of XLCART001 in treatment of relapsed/refractory/high-risk B-cell malignancy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | chimeric antigen receptor T cells | Dose CAR+ cells/kg B-cell lymphoma 4×10\^6 Acute lymphocytic leukemia 2×10\^6 Chronic lymphocytic leukemia 10×10\^6 |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2019-12-30
- Completion
- 2020-07-01
- First posted
- 2018-07-26
- Last updated
- 2019-08-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03598179. Inclusion in this directory is not an endorsement.